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JAAD ONLINE: NOTES &
Tapinarof cream 1% once daily and
benvitimod 1% twice daily are 2
distinct topical medications
To the Editor: We thank Assaf et al for their review of
the future of topical therapy for plaque psoriasis and
share their conclusion that tapinarof, a therapeutic
aryl hydrocarbon receptor-modulating agent, has the
potential to be a much needed option for the
treatment of psoriasis.
We would like to provide a clarification on the key
points of difference between tapinarof cream 1%
once daily and benvitimod 1% twice daily because
Assaf et al inadvertently conflated the aspects of
these distinct topical medications that contain the
same active component (3,5-dihydroxy-4-isopropyltrans-stilbene).
Tapinarof cream 1%, acquired by Dermavant
Sciences, Inc, from GlaxoSmithKline, comprises
a novel vehicle, with specific excipients to enhance
efficacy, product delivery, and patient acceptability,
resulting in a cosmetically elegant, once-daily,
steroid-free cream, which is under clinical development. The benvitimod 1% formulation, which is not
licensed to Dermavant Sciences, Inc, includes
different excipients (eg, petrolatum) and requires
twice-daily dosing, a potentially, clinically relevant
adherence barrier. Furthermore, the tapinarof and
benvitimod formulations are being investigated
in separate clinical trials, with important differences
in their designs.
Tapinarof cream 1% once daily has been evaluated in multiple North American centers in 2 phase
2b dose-ranging trials,1,2 2 phase 3 pivotal trials
(PSOARING 1 and 2),3 and a long-term extension
trial (PSOARING 3).4 As correctly reported by Assaf
et al, tapinarof demonstrated a highly, statistically
significant efficacy compared with the vehicle,
reaching its primary endpoint (P \ .0001) in the
pivotal phase 3 trials.3 However, the primary
endpoint in PSOARING 1 and 2 was the more
stringent US Food and Drug Administration requirement of achieving a physician global assessment
(PGA) score of 0 or 1 and at least a 2-grade
improvement from baseline rather than a PGA score
of 0 or 1 as stated by Assaf et al and as used in the
Chinese benvitimod 1% trial.5
The pivotal tapinarof and benvitimod trials differ
in other important respects. In PSOARING 1 and 2,
1025 patients with mild-to-severe plaque psoriasis
were randomized to receive either tapinarof or the
vehicle once daily; whereas, in the trial by Cai et al5
in 2020, 344 patients with mild-to-moderate plaque
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psoriasis were randomized to receive benvitimod
twice daily.
Moreover, in an interim analysis of PSOARING 3,
tapinarof cream 1% once daily demonstrated a
remittive effect for approximately 4 months, defined
as the maintenance of a PGA score of 0 or 1 (clear or
almost clear) while off therapy after achieving complete disease clearance (PGA score of 0).4 The
duration of remittive benefit with tapinarof may
actually be [ 4 months because the study’s end
truncated the window of observation. In the benvitimod trial, by contrast, 59 patients achieving a PGA
score of 0 or 1 by week 12 were followed up, of
whom 29 maintained the resolution at 52 weeks.5
In summary, tapinarof cream 1% once daily and
benvitimod 1% twice daily are 2 distinct topical
medications being assessed in separate clinical trial
programs. While the benvitimod trial5 provides additional confirmation of the clinical potential of the
active principle, differences in the formulation and
study design mean that direct comparisons between
these investigational topical medications and between their clinical data should be made with caution.
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